Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Auckland, New Zealand. In Drugs, Dec 2015
Complete response rates during the delayed, acute and overall phases were significantly higher with single-dose netupitant 300 mg plus palonosetron 0.5 mg than with single-dose palonosetron 0.5 mg in cycle 1 of cisplatin-based highly emetogenic chemotherapy (HEC) in a phase II trial and with single-dose netupitant/palonosetron 300/0.5 mg than with single-dose palonosetron 0.5 mg in cycle 1 of anthracycline-cyclophosphamide (AC) moderately emetogenic chemotherapy (MEC) in a phase III trial; the greater efficacy of netupitant/palonosetron was maintained over repeated cycles of AC MEC in the phase III trial.
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.
South Bend, United States. In Biomed Res Int, 2014
Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30-50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthrough CINV.
A blueprint for kinetochores - new insights into the molecular mechanics of cell division.
More papers using
Vienna, Austria. In Nat Rev Mol Cell Biol, 2011
In the past decade, concerted research has resulted in the identification of the individual kinetochore building blocks, the characterization of critical microtubule-interacting components, such as the NDC80 complex, and the development of an approximate model of the architecture of this sophisticated biological machine.
Chlorpromazines and cancer
In Apoptosis, 1971
... Human cervical (HeLa, C33A and Caski) and endometrial (HEC-1-A and KLE) cancer cell lines were maintained in DMEM (Life Technologies, Gaithersburg, MD) and RPMI1640 ...